Skip to content

Trial · Interventional

CompletedPhase 1Results postedRegistry data

A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults

NCTNCT05137730 (opens ClinicalTrials.gov in a new tab)Other idTAK-834-1001
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 1
Enrollment
96 participants (actual)
Sponsor
Takeda · Industry
Design
Randomized · Open label (no masking)
Countries
1 country

United States

Start
29 Nov 2021
Primary completion
15 Apr 2022
Completion
15 Apr 2022
First posted
30 Nov 2021
Last update posted
15 Dec 2023
Conditions
Healthy Volunteers

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202120222023
  1. Ph 1

    A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults

    NCT05137730

    29 Nov 2021 to 15 Apr 2022

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The main aim of Part I of this study is to evaluate the relative bioavailability of a new formulation compared with the approved formulation when a single dose of rhPTH(1-84) is given to healthy volunteers. Bioavailability is the ability of a drug to be absorbed and used by the body. In Part II, the main aim is to assess the dose linearity of the new formulation. Participants will receive 2 doses in Part I and 4 doses in Part II. Participants need to visit their doctor approximately 14 days and 30 days after the last dose of study drug.

Interventions

  • rhPTH(1-84)Drug

Arms6

  • Experimental

    Part I: Sequence AB

    Participants will receive a single SC injection of 100 microgram (mcg) rhPTH(1-84) (Formulation A) on Day 1 of treatment period 1 followed by 100 mcg rhPTH(1-84) (Formulation B) on Day 1 of treatment period 2. A washout period of 96 hours will be maintained between each treatment period.

  • Experimental

    Part I: Sequence BA

    Participants will receive a single SC injection of 100 microgram (mcg) rhPTH(1-84) (Formulation B) on Day 1 of treatment period 1 followed by 100 mcg rhPTH(1-84) (Formulation A) on Day 1 of treatment period 2. A washout period of 96 hours will be maintained between each treatment period.

  • Experimental

    Part II: Sequence CDEF

    Participants will receive a single SC injection of 25 mcg (dose C) rhPTH(1-84) on Day 1 of treatment period 1 followed by 50 mcg (dose D) rhPTH(1-84) on Day 1 of treatment period 2 followed by 75 mcg (dose E) rhPTH(1-84) on Day 1 of treatment period 3 followed 200 mcg (dose F) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.

  • Experimental

    Part II: Sequence DFCE

    Participants will receive a single SC injection of 50 mcg (dose D) rhPTH(1-84) on Day 1 of treatment period 1 followed by 200 mcg (dose F) rhPTH(1-84) on Day 1 of treatment period 2 followed by 25 mcg (dose C) rhPTH(1-84) on Day 1 of treatment period 3 followed by 75 mcg (dose E) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.

  • Experimental

    Part II: Sequence ECFD

    Participants will receive a single SC injection of 75 mcg (dose E) rhPTH(1-84) on Day 1 of treatment period 1 followed by 25 mcg (dose C) rhPTH(1-84) on Day 1 of treatment period 2 followed by 200 mcg (dose F) rhPTH(1-84) on Day 1 of treatment period 3 followed by 50 mcg (dose D) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.

  • Experimental

    Part II: Sequence FEDC

    Participants will receive a single SC injection of 200 mcg (dose F) rhPTH(1-84) on Day 1 of treatment period 1 followed by 75 mcg (dose E) rhPTH(1-84) on Day 1 of treatment period 2 followed by 50 mcg (dose D) rhPTH(1-84) on Day 1 of treatment period 3 followed by 25 mcg (dose C) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.

Primary outcomes7

Outcomes the sponsor listed as primary.

  1. Part I: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84)

    Time frame · Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose

    Registry description

    AUClast was a measure of the total amount of drug in the plasma from time zero to time of the last measurable concentration.

  2. Part II: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84)

    Time frame · Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose

    Registry description

    AUClast was a measure of the total amount of drug in the plasma from time zero to time of the last measurable concentration.

  3. Part I: Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity (AUCinf) of rhPTH(1-84)

    Time frame · Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose

    Registry description

    AUCinf was the area under the curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration. AUC was be used as a measure of drug exposure. It was derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

  4. Part II: Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity (AUCinf) of rhPTH(1-84)

    Time frame · Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose

    Registry description

    AUCinf was the area under the curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration. AUC was be used as a measure of drug exposure. It was derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

  5. Part I: Maximum Observed Plasma Concentration (Cmax) of rhPTH(1-84)

    Time frame · Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose

    Registry description

    Cmax referred to the maximum (or peak) concentration that a drug achieved in the body after the drug had been administrated.

  6. Part II: Maximum Observed Plasma Concentration (Cmax) of rhPTH(1-84)

    Time frame · Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose

    Registry description

    Cmax referred to the maximum (or peak) concentration that a drug achieved in the body after the drug had been administrated.

  7. Number of Participants With Clinically Significant Changes in Vital Signs Values

    Time frame · From start of study drug administration up to Day 34

    Registry description

    Vital sign assessments included systolic and diastolic blood pressure, pulse rate and body temperature. Any change in vital signs which are deemed clinically significant by the investigator were reported.

Secondary outcomes(3)

  1. Part I and II: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame · From start of study drug administration up to Day 34

    Registry description

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was an adverse event with a start date on or after the first dose of Investigational product (IP), or a start date before the date of the first dose of IP but increased in severity on or after the date of the first dose of IP. Number of participants with TEAEs was reported.

  2. Part I and II: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters Reported as TEAEs

    Time frame · From start of study drug administration up to Day 34

    Registry description

    Any change in ECG assessments which were deemed clinically significant by the investigator were reported.

  3. Part I and II: Number of Participants With Clinically Significant Changes in Clinical Laboratory Values

    Time frame · From start of study drug administration up to Day 34

    Registry description

    Clinical laboratory tests included hematology, chemistry, and urinalysis. Any changes in clinical laboratory results which are deemed clinically significant by the investigator were reported.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeGeometric mean· Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose

Part I: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84)

GroupValue (picogram*hour/milliliter (pg*hr/ml))Spread
Part I: Treatment A471.957.4
Part I: Treatment B603.150.3
Primary outcomeGeometric mean· Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose

Part II: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84)

GroupValue (pg*hr/ml)Spread
Part II: Treatment C44.34161.7
Part II: Treatment D97.74123.4
Part II: Treatment E259.257.5
Part II: Treatment F100961.3
Primary outcomeGeometric mean· Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose

Part I: Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity (AUCinf) of rhPTH(1-84)

GroupValue (pg*hr/ml)Spread
Part I: Treatment A559.753.2
Part I: Treatment B663.744.0
Primary outcomeGeometric mean· Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose

Part II: Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity (AUCinf) of rhPTH(1-84)

GroupValue (pg*hr/ml)Spread
Part II: Treatment C83.9119.5
Part II: Treatment D217.033.2
Part II: Treatment E364.739.0
Part II: Treatment F111759.6
Primary outcomeGeometric mean· Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose

Part I: Maximum Observed Plasma Concentration (Cmax) of rhPTH(1-84)

GroupValue (picogram per milliliter (pg/ml))Spread
Part I: Treatment A150.853.2
Part I: Treatment B185.152.7
Primary outcomeGeometric mean· Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose

Part II: Maximum Observed Plasma Concentration (Cmax) of rhPTH(1-84)

GroupValue (pg/ml)Spread
Part II: Treatment C28.0550.4
Part II: Treatment D43.0647.5
Part II: Treatment E77.4655.8
Part II: Treatment F250.241.5
Primary outcomeCount of participants· From start of study drug administration up to Day 34

Number of Participants With Clinically Significant Changes in Vital Signs Values

GroupValue (Participants)
Part I: Treatment A1
Part I: Treatment B0
Part II: Treatment C0
Part II: Treatment D0
Part II: Treatment E0
Part II: Treatment F0
Secondary and other outcome results(1)
Secondary outcomeCount of participants· From start of study drug administration up to Day 34

Part I and II: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

GroupValue (Participants)
Part I: Treatment A19
Part I: Treatment B15
Part II: Treatment C2
Part II: Treatment D4
Part II: Treatment E3
Part II: Treatment F2

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
Part I: Treatment AParticipants received a single SC injection of 100 mcg rhPTH(1-84) (Treatment A) on Day 1 of one of the two treatment periods.0 / 840 / 8410 / 84
Part I: Treatment BParticipants received a single SC injection of 100 mcg rhPTH(1-84) (Treatment B) on Day 1 of one of the two treatment periods.0 / 840 / 849 / 84
Part II: Treatment CParticipants received a single SC injection of 25 mcg (Treatment C) rhPTH(1-84) on Day 1 of one of the four treatment periods.0 / 120 / 122 / 12
Part II: Treatment DParticipants received a single SC injection of 50 mcg (Treatment D) rhPTH(1-84) on Day 1 of one of the four treatment periods.0 / 120 / 124 / 12
Part II: Treatment EParticipants received a single SC injection of 75 mcg (Treatment E) rhPTH(1-84) on Day 1 of one of the four treatment periods.0 / 120 / 123 / 12
Part II: Treatment FParticipants received a single SC injection of 200 mcg (Treatment F) rhPTH(1-84) on Day 1 of one of the four treatment periods.0 / 120 / 122 / 12

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 65 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: Participants must fulfill all of the following inclusion criteria to be eligible for participation in the study: * Healthy, adult, male or female, 18-65 years of age, inclusive, at screening. Attempts will be made to enroll at least 20% of each sex in each study part. * Continuous non-smoker who has not used nicotine containing products for at least 90 days prior to the first dosing and throughout the study, based on participant self-reporting. * Body mass index (BMI) greater than or equal to (\>=) 18.5 and less than or equal to (\<=) 30.0 kilogram per square meter (kg/m2) at screening. * Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the Investigator or designee including the following: * Serum calcium, parathyroid hormone (PTH), phosphate, and magnesium within laboratory normal limits at screening and check-in. * Vitamin D (1,25(OH)2D3) levels between lower limit of normal and up to 1.5x Upper Limit of Normal (ULN). * Seated blood pressure Beats per minute (bpm) is \>= 89/49 millimeters of mercury (mmHg) and \<=139/89 mmHg at screening. * Seated pulse rate is \>=40 bpm and \<=99 bpm at screening. * QTcF interval is \<=450 millisecond (msec) (males) or \<= 470 msec (females) or ECG findings considered normal or not clinically significant by the Investigator or designee at screening. * Estimated creatinine clearance \>= 80 milliliter per minute (mL/minute) at screening. * Agrees to comply with any applicable contraceptive requirements of the protocol. * Understands the study procedures in the ICF, be able to voluntarily provide written, signed, and dated informed consent, and be willing and able to comply with the protocol. Exclusion Criteria: Participants must not be enrolled in the study if they meet any of the following criteria: * Mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study in the opinion of the Investigator or designee. * History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the Investigator or designee. * History of any hematological, hepatic, respiratory, cardiovascular, renal, neurological or psychiatric disease, gall bladder removal, or current or recurrent disease that could affect the action, absorption, or disposition of the study drug, or clinical or laboratory assessments. * Participants who are at increased baseline risk for osteosarcoma such as participants with Paget's disease of bone or unexplained elevations of alkaline phosphatase (ALP), hereditary disorders predisposing to osteosarcoma or a prior history of external beam or implant radiation therapy involving the skeleton. * History of any illness that, in the opinion of the Investigator or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study. * History or presence of alcoholism or drug abuse, in the opinion of the Investigator or designee, within the past 2 years prior to the first dosing. * Male participants who consume more than 21 units of alcohol per week or 3 units per day. Female participants who consume more than 14 units of alcohol per week or 2 units per day. (1 alcohol unit=1 beer or 1 wine (5 ounces (oz)/150 in milliliters (mL) or 1 liquor (1.5 oz/40 mL) or 0.75 oz alcohol). * Positive urine drug or alcohol results at screening or check-in. * History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds. * History of abnormalities of calcium homeostasis including hyperparathyroidism, hypoparathyroidism, hyperthyroidism, Cushing's syndrome, hypercalcemia, hypocalcemia, osteoporosis, or any other calcium disorder. * Female participants who have a positive pregnancy test or who are lactating. * Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV). * Has tattoo(s) or scarring at or near the site of injection or any other condition which may interfere with injection site examination, in the opinion of the Investigator or designee. * Routine consumption of more than 2 units of caffeine per day or participants who experience caffeine withdrawal headaches. A unit of caffeine is contained in the following items: one 6 oz (180 mL) cup of coffee, two 12 oz (360 mL) cans of cola, one 12 oz cup of tea, three 1 oz (85 g) chocolate bars. * Prior screen failure, randomization, participation, or enrollment in this study or prior exposure to any exogenous PTH, PTH fragments or analogs 3 months prior to dosing with rhPTH(1-84). * Unable to refrain from or anticipates the use of any medication or substance (including prescription or over-the-counter, vitamin supplements, natural or herbal supplements) Medication, Supplements, and Dietary Products) for the prohibited time period. * Has been on a diet incompatible with the study diet or had any substantial changes in eating habits, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing and throughout the study. * Donation of blood or significant blood loss within 60 days prior to the first dosing. * Plasma donation within 7 days prior to the first dosing. * Participation in another clinical study within 30 days or 5 half-lives of the study drug prior to the first dosing. The 30-day window or 5 half-lives will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Treatment Period 1 of the current study.

PepBank is a research reference. Talk to a doctor before you use any peptide.